Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...

Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. Read more on TVTX stock here.

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, ...

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...

Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

For the quarter ended December 2025, Travere Therapeutics (TVTX) reported revenue of $129.69 million, up 73.4% over the same period last year. EPS came in at $0.03, compared to -$0.73 in the year-ago ...

Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $0.24. The market awaits Travere ...

Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

The drug developer posted revenue of $129.7 million in the period, which did not meet Street forecasts. Six analysts surveyed by Zacks expected $142.5 million. For the year, the company reported a ...

FILSPARI generated $103.3 million in U.S. net product sales for Q4 and $322 million for the full year. Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 and $88.5 ...

Travere Therapeutics (NASDAQ: TVTX) reported its Q4 earnings results on Thursday, February 19, 2026 at 04:01 PM. Here's what investors need to know about the announcement. Travere Therapeutics beat ...